Dicerna Pharmaceuticals Logo

Email this page: News Release

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)

For security reasons, registration is required before you can use this feature.
* Indicates required field